Genetic predisposition to prostate cancer: Update and future perspectives
- PMID: 24996773
- DOI: 10.1016/j.urolonc.2014.04.021
Genetic predisposition to prostate cancer: Update and future perspectives
Abstract
Objective: Prostate cancer is the second most frequent cancer in men worldwide and kills over 250,000 men worldwide every year. Prostate cancer is a heterogeneous disease at the clinical and the molecular level. The Scandinavian Twin Registry Study demonstrated that in contrast to most malignancies where environment was the overriding influence, heritable factors account for more than fifty percent of prostate cancers.
Methods and materials: We review the literature on prostate cancer risk variants (rare and common) including SNPs and Copy Number Variants (CNVs) and discuss the potential implications of significant variants for prostate cancer patient care.
Results: The search for prostate cancer susceptibility genes has included both family-based studies and case-control studies utilizing a variety of approaches from array-based to sequencing-based studies. A major challenge is to identify genetic variants associated with more aggressive, potentially lethal prostate cancer and to understand their role in the progression of the disease.
Conclusion: Future risk models useful in the clinical setting will likely incorporate several risk loci rather than single variants and may be dependent on an individual patient's ethnic background.
Keywords: CNV; Common variants; Prostate cancer risk; Rare variants; SNP.
Copyright © 2014 Elsevier Inc. All rights reserved.
Similar articles
-
Perspective: prostate cancer susceptibility genes.Endocrinology. 2002 Jun;143(6):2029-40. doi: 10.1210/endo.143.6.8890. Endocrinology. 2002. PMID: 12021166 Review.
-
Prostate cancer risk variants are not associated with disease progression.Prostate. 2012 Jan;72(1):30-9. doi: 10.1002/pros.21403. Epub 2011 Apr 25. Prostate. 2012. PMID: 21520160
-
Hereditary/familial versus sporadic prostate cancer: few indisputable genetic differences and many similar clinicopathological features.Eur Rev Med Pharmacol Sci. 2010 Jan;14(1):31-41. Eur Rev Med Pharmacol Sci. 2010. PMID: 20184087 Review.
-
Genetic variations in VDR associated with prostate cancer risk and progression in a Korean population.Gene. 2014 Jan 1;533(1):86-93. doi: 10.1016/j.gene.2013.09.119. Epub 2013 Oct 9. Gene. 2014. PMID: 24120391
-
Sequence variants in Toll-like receptor gene cluster (TLR6-TLR1-TLR10) and prostate cancer risk.J Natl Cancer Inst. 2005 Apr 6;97(7):525-32. doi: 10.1093/jnci/dji070. J Natl Cancer Inst. 2005. PMID: 15812078
Cited by
-
Association of fatty-acid synthase polymorphisms and expression with outcomes after radical prostatectomy.Prostate Cancer Prostatic Dis. 2015 Jun;18(2):182-9. doi: 10.1038/pcan.2015.11. Epub 2015 Apr 14. Prostate Cancer Prostatic Dis. 2015. PMID: 25868764 Free PMC article.
-
An integrative multi-omics analysis to identify candidate DNA methylation biomarkers related to prostate cancer risk.Nat Commun. 2020 Aug 6;11(1):3905. doi: 10.1038/s41467-020-17673-9. Nat Commun. 2020. PMID: 32764609 Free PMC article.
-
Novel strategy for disease risk prediction incorporating predicted gene expression and DNA methylation data: a multi-phased study of prostate cancer.Cancer Commun (Lond). 2021 Dec;41(12):1387-1397. doi: 10.1002/cac2.12205. Epub 2021 Sep 14. Cancer Commun (Lond). 2021. PMID: 34520132 Free PMC article.
-
Expression of Peroxisome Proliferator Activated Receptor gamma in Prostatic Adenocarcinoma.J Korean Med Sci. 2015 May;30(5):533-41. doi: 10.3346/jkms.2015.30.5.533. Epub 2015 Apr 15. J Korean Med Sci. 2015. PMID: 25931782 Free PMC article.
-
Identification of Novel Susceptibility Loci and Genes for Prostate Cancer Risk: A Transcriptome-Wide Association Study in Over 140,000 European Descendants.Cancer Res. 2019 Jul 1;79(13):3192-3204. doi: 10.1158/0008-5472.CAN-18-3536. Epub 2019 May 17. Cancer Res. 2019. PMID: 31101764 Free PMC article.
Publication types
MeSH terms
Grants and funding
LinkOut - more resources
Full Text Sources
Medical